#MEDIA – At #APVRS2026, we're pleased to share new two-year data for our treatment in patients with PCV, a severe sub-type of nAMD – the leading cause of vision loss in people over 60. roche.com/media
Roche
@Roche
We advance science so that we all have more time with the people we love.
Read our community guidelines: go.roche.com/CG
